Jefferies reiterates Illumina stock Hold rating on innovation potential
Jefferies maintained a Hold rating on Illumina (ILMN) with a $235 price target, citing innovation in SomaSeq and TruPath. The stock is up 80% year-over-year. Q3 2026 earnings beat estimates, with revenue of $1.17B and EPS of $1.44. Evercore ISI raised its target to $200 but kept an Underperform rating. ILMN's gross margin is 68% on $4.5B revenue, though some analysts cut earnings estimates.
How this was made
The 30-second read
Why it matters
Analyst rating and target provide a fresh data point for traders; the price gap may attract buying interest.
Market read
New analyst rating offers a modest trading edge for ILMN; broader market impact is minimal.
What to watch
Early adoption of SomaSeq and TruPath could accelerate revenue if pilots convert to commercial sales.
Background
Jefferies' reiteration follows a recent tour of Illumina's facilities and a strong Q3 earnings beat.
Ticker impact
Jefferies reiterated a Hold rating on Illumina with a $235 price target after touring its Cambridge facility and noting Q3 earnings beat.
modest upside pressure as the market prices in the higher $235 target versus current $154 price
The rating and target are fresh analyst input; no immediate catalyst but the sizable gap suggests potential upside.
Market effects
May reinforce positive sentiment for the genomics sequencing sector as Illumina remains a benchmark.
Limited to US biotech equities.
Low; impact confined to Illumina and peers.
Counterpoint
The Hold rating suggests limited upside; investors may wait for clearer growth catalysts.
Key entities
- companyIllumina Inc.
US-listed genomics sequencing firm.
- analystJefferies
Equity research firm issuing the Hold rating.


